CoverageForm 410-K10-Q8-K13D13G13F

IRTC · Irhythm Holdings, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · IRTC

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue$199.39M-$192.88M$186.69M$158.68M-$147.54M$148.05M$131.93M-
Cost of Revenue$58.04M-$55.76M$53.83M$49.46M-$46.06M$44.58M$44.41M-
Gross Profit$141.35M-$137.12M$132.86M$109.22M-$101.48M$103.47M$87.52M-
R&D$21.36M-$21.03M$21.01M$16.99M-$16.31M$19.69M$16.99M-
SG&A$135.88M-$124.22M$126.38M$119.96M-$103.38M$106.76M$108.66M-
Total Operating Expenses$157.54M-$145.55M$151.56M$141.77M-$151.78M$126.45M$125.65M-
D&A$5.00M-$5.20M$5.10M$5.20M-$5.10M$5.20M$5.10M-
Operating Income($16.18M)-($8.43M)($18.71M)($32.56M)-($50.30M)($22.98M)($38.14M)-
Interest Expense$3.29M-$3.28M$3.28M$3.27M-$3.27M$0$2.86M-
Income Tax$500.0K-$24.0K($183.0K)$665.0K-$188.0K$194.0K$32.0K-
Net Income($13.93M)-($5.21M)($14.22M)($30.70M)-($46.18M)($20.11M)($45.67M)-
EPS - Basic($0.43)-($0.16)($0.44)($0.97)-($1.48)($0.65)($1.47)-
EPS - Diluted($0.43)-($0.16)($0.44)($0.97)-($1.48)($0.65)($1.47)-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$240.15M$236.01M$255.60M$309.11M$375.28M$419.60M$519.53M$550.55M$520.42M$36.17M
Accounts Receivable$80.86M$75.71M$76.16M$82.15M$80.64M$79.94M$77.43M$85.51M$89.71M$61.48M
Inventory$23.80M$21.63M$19.56M$18.40M$14.34M$14.04M$15.03M$15.43M$14.87M$13.97M
Accounts Payable$8.56M$2.26M$8.28M$12.78M$11.95M$7.22M$7.59M$13.43M$8.44M$5.54M
Current Assets$680.56M$702.76M$680.03M$663.92M$636.01M$645.82M$627.91M$677.51M$687.46M$230.81M
Total Assets$1.01B$1.02B$995.21M$964.03M$926.10M$931.45M$909.69M$919.18M$909.75M$433.14M
Current Liabilities$131.75M$151.89M$146.91M$132.21M$111.34M$110.92M$100.10M$97.89M$96.84M$107.37M
Long-term Debt---------$34.95M
Total Liabilities$845.15M$867.30M$873.32M$860.37M$839.43M$840.54M$837.92M$820.00M$819.47M$223.05M
Stockholders' Equity$161.21M$152.75M$121.89M$103.66M$86.67M$90.91M$71.77M$99.19M$90.29M$210.10M
Retained Earnings($817.38M)($803.45M)($809.02M)($803.81M)($789.60M)($758.89M)($757.56M)($711.38M)($691.27M)($645.61M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($26.17M)---($7.89M)---($52.03M)-
Investing Cash Flow$30.21M---($38.14M)---$40.00M-
Financing Cash Flow$149.0K---$1.73M---$504.64M-
CapEx$6.91M---$9.42M---$9.78M-
Free Cash Flow($33.08M)---($17.31M)---($61.80M)-

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin70.9%-71.1%71.2%68.8%-68.8%69.9%66.3%-
Operating margin-8.1%--4.4%-10.0%-20.5%--34.1%-15.5%-28.9%-
EBITDA margin-5.6%--1.7%-7.3%-17.2%--30.6%-12.0%-25.0%-
Net margin-7.0%--2.7%-7.6%-19.3%--31.3%-13.6%-34.6%-
Free cash flow margin-16.6%----10.9%----46.8%-
FCF / Net income2.37---0.56---1.35-
R&D / Revenue10.7%-10.9%11.3%10.7%-11.1%13.3%12.9%-
SG&A / Revenue68.1%-64.4%67.7%75.6%-70.1%72.1%82.4%-
Effective tax rate----------
Return on assets-1.4%--0.5%-1.5%-3.3%--5.1%-2.2%-5.0%-
Return on equity-8.6%--4.3%-13.7%-35.4%--64.4%-20.3%-50.6%-
Return on invested capital----------
Liquidity
Current ratio5.174.634.635.025.715.826.276.927.102.15
Quick ratio4.984.484.504.885.585.706.126.766.952.02
Cash ratio1.821.551.742.343.373.785.195.625.370.34
Leverage
Debt / Equity---------0.17
Debt / Assets---------0.08
Debt / EBITDA----------
Interest coverage-4.9x--2.6x-5.7x-9.9x--15.4x--13.3x-
Equity multiplier6.246.688.169.3010.6910.2512.689.2710.082.06
Liabilities / Assets0.840.850.880.890.910.900.920.890.900.51
Efficiency
Asset turnover0.20-0.190.190.17-0.160.160.15-
Inventory turnover2.44-2.852.933.45-3.062.892.99-
Days sales outstanding148d-144d161d185d-192d211d248d-
Days inventory outstanding150d-128d125d106d-119d126d122d-
Days payable outstanding54d-54d87d88d-60d110d69d-
Cash conversion cycle244d-218d199d203d-250d227d301d-
Valuation
P / E----------
P / B23.8x-45.4x47.5x38.2x-32.3x33.8x39.9x-
P / S19.2x-28.7x26.4x20.8x-15.7x22.6x27.3x-
EV / EBITDA----------
Growth
Revenue growth (YoY)25.7%-30.7%26.1%20.3%-18.4%19.3%18.4%-
Revenue CAGR (3y)21.4%-22.9%22.3%19.8%-20.0%22.1%21.1%-
Revenue CAGR (5y)21.8%-21.8%29.7%20.1%-22.0%22.7%22.8%-
Gross profit growth (YoY)29.4%-35.1%28.4%24.8%-23.0%20.0%15.6%-
Operating income growth (YoY)50.3%-83.2%18.6%14.6%--82.2%-21.8%3.5%-
Net income growth (YoY)54.6%-88.7%29.3%32.8%--70.3%-8.8%-16.8%-
EPS growth (YoY)55.7%-89.2%32.3%34.0%--66.3%-6.6%-14.0%-
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)-91.1%---72.0%----57.8%-
FCF CAGR (5y)----------
Book value growth (YoY)86.0%68.0%69.8%4.5%-4.0%-56.7%-67.3%-55.7%-59.3%-12.4%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Product / service

$747.14M total
Commercial Payors$392.23M · 52.5%
Centers For Medicare And Medicaid$179.35M · 24.0%
Healthcare Institutions$125.61M · 16.8%
Non Contracted Third Party Payors$49.94M · 6.7%

Peer comparison

Same SIC group: Surgical & Medical Instruments & Apparatus

CompanyRevenue (last FY)Net marginROE
BSX$20.07B14.4%12.0%
LMAT$249.60M23.1%14.7%
TNDM$1.01B-20.2%-131.9%
SYK$25.12B12.9%14.5%
MMM$24.95B13.0%69.1%

Comparing iRhythm Holdings against the 5 most active filers in the same SIC group.